Weekly Recap | July - W4
Updated Watchlist & Buying Targets, China Trade Talks, Transmedics' Saga, GLP-1 Compounders, PayPal's Innovations, Tesla News, Weekly Planning & Earnings Review (Enphase, Intuitive Surgery & LVMH).
Weekly Buying List Update.
Here is my watchlist & buying plan. Reaching those prices does not mean I always pull the trigger, those are only my view of valuation & price action today, I only pull the triggers on the ones I believe to be the best liquidity attribution at the moment - purchases are shared on my Savvy B&H portfolio.
https://savvytrader.com/wealthyreadingspro/buyandhodl
“OCB” - Optimized Cost Basis, the optimum average price for a long term position.
“Accumulation Target” - buying target based on price action, to average up.
“DCA” - trading at a proper price to open a position or accumulate.
“Accumulation” - trading at a proper price to average up an already existing position with an average below OCB.
Bold cells are updates compared to last week.
Macro.
No significant news to share here this week if we want to stay on the economy side of things - and that’s what I want to do, so I’ll stop there.
The only interesting piece is another 90-day delay in tariffs announced Sunday, which is not really surprising as both countries’ representatives have to meet in Sweden this week to pursue the trade talks & hopefully reach an agreement - a positive one.
Thankfully, the entire mess seems to be slowing down while the market doesn’t move much to the news anymore as it knows things can change depending on the White House’s mood each morning.
This is good news for international trade & the markets - especially the Chinese one, which is on the verge of starting a bull run. I shared in a note this week that net inflows towards Chinese securities were rising rapidly.
I’ll repeat myself - that’s what I do, do not sleep on China, if only to inform yourself, as investing there is another question. Put your bias aside; the country is not ruled by Mao anymore & communism as detailed in our history book is long dead there. The government has an iron grip, but this doesn’t lead to all-in communism. Inform yourself. Watch videos. Hell, take a plane ticket & see for yourself; anyone I’ve seen going there recently came back baffled, by the progress, their life quality but also the atmosphere & how everything is different from their expectations.
Once again, Mao is dead. And the world is changing.
Watched Stocks and Portfolio.
The Transmedics Saga.
I talk a lot about this name because, as shared yesterday, I believe it to be the best opportunity on the market right now as the stock is beaten down due to stories & bearish speculation, which are honestly not serious.
Everything important was shared through notes & you’ll find it all here.
Hims & The GLP-1 Industry.
Something is happening in the GLP-1 market & the healthcare industry at large as two different GLP-1 sellers have restarted selling compounded versions this week, starting to advertise again & have those products selling on their websites.
For context, compounded GLP-1 should not be authorized anymore, even from 503B pharmacies, since the shortage has been resolved. Hims is playing on the lines with its personalized solutions, supposed to fill a small gap in dosage from patented drugs & answer a specific needs unanswered by pattented drugs. A fine line, but a legal one for now at least, which costed them their partnership with Novo Nordisk.
Others decided to play good boys with the two official providers, Novo Nordisk & Eli Lilly, in exchange for selling their FDA-approved drugs on their platforms.
For a reason I - and the internet - do not understand yet, two of those decided to go against the giants & accept breaking their partnership with them to sell compounded GLP-1 again - like Hims is doing. This happens after a few losses in courts by the two giants on GLP-1 related subject.
Are some companies taking risks, being ballsy, or simply playing the game under new rules? Hard to know, but something made them dare to restart this service. Bulls will see it as good news, as it could mean Hims was right all along. Bears could say they’ll all eventually be shut down when one patent lawsuit emerges… but we’re still waiting for it to happen, months later.
Hard to make a sense to it all. But the situation remains volatile.
PayPal Innovations.
AI continues to transform the world and, soon enough, the world of online shopping. And I have not seen any payment provider improve or share new services to answer this new use case - all of them are focused on stablecoins.
None, but PayPal - who launched its stablecoin more than a year ago.
It might be time to change the narrative around the name as the dinosaur has been first in a few different innovations lately - stablecoins with its PYUSD, improved checkout with Fastlane and LLMs’ integration with Perplexity’s partnership.
And now, PayPal World for travelers & international payments, somehting which should happen more often than before with LLMs.
Tesla News.
I have covered Tesla’s earnings this week with the most unbiased tone I could - the data was so bad it made the exercise easy, but some things are improving for the company, starting with their EV business opening in India.
They also opened their diner, which I called a small cult place centered around Musk’s companies - not in a bad way. I’d personally gladly go get a burger there.
This won’t impact the business, but Tesla is more than an EV manufacturer; it is a brand and an entire ecosystem, and with the damage done to it over the last two years, this kind of place could do some good.
There would be other ways to do some good - Musk going back to his companies & avoiding politics altogether, but well…
Weekly Planning.
Big week coming. Detailed write-up planned for PayPal, Meta & TransMedics. Spotify, SoFi, Starbucks, Robinhood & Apple will have a detailed note. And some comments or maybe detailed notes for the others if the data is interesting.
Earnings.
Here are the notes I sent on the companies I follow but do not have a detailed write-up on for different reasons, the main one being that I do not consider them important opportunities yet. They will have detailed write up if/when opportunities arise.